| Literature DB >> 26158290 |
Jianguo Zhu1,2, Cong Pan1, Jun Jiang3, Mingsen Deng1, Hengjun Gao4, Bozhao Men5, Michael McClelland5, Dan Mercola6, Wei-D Zhong7, Zhenyu Jia1,8,9.
Abstract
We previously analyzed human prostate tissue containing stroma near to tumor and from cancer-negative tissues of volunteers. Over 100 candidate gene expression differences were identified and used to develop a classifier that could detect nearby tumor with an accuracy of 97% (sensitivity = 98% and specificity = 88%) based on 364 independent test cases from primarily European American cases. These stroma-based gene signatures have the potential to identify cancer patients among those with negative biopsies. In this study, we used prostate tissues from Chinese cases to validate six of these markers (CAV1, COL4A2, HSPB1, ITGB3, MAP1A and MCAM). In validation by real-time PCR, four genes (COL4A2, HSPB1, ITGB3, and MAP1A) demonstrated significantly lower expression in tumor-adjacent stroma compared to normal stroma (p value ≤ 0.05). Next, we tested whether these expression differences could be extended to the protein level. In IHC assays, all six selected proteins showed lower expression in tumor-adjacent stroma compared to the normal stroma, of which COL4A2, HSPB1 and ITGB3 showed significant differences (p value ≤ 0.05). These results suggest that biomarkers for diagnosing prostate cancer based on tumor microenvironment may be applicable across multiple racial groups.Entities:
Keywords: diagnosis; microenvironment; prostate cancer; race; stroma
Mesh:
Substances:
Year: 2015 PMID: 26158290 PMCID: PMC4599305 DOI: 10.18632/oncotarget.4430
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The results of RT-qPCR
A. The electrophoresis of PCR product for six genes. B. Histogram for the relative expression levels for six genes. NS: normal stroma; TS: tumor adjacent stroma; *P < 0.05, **P < 0.01.
Figure 2a. The stroma component selected for differential expression analysis. The images presented in the figure were obtained from IHC analysis of MCAM. Samples labeled with black/red represent, respectively, tumor-bearing and tumor-adjacent tissues from patients' prostate glands; samples labelled with green are prostate tissue from normal subjects. b. Representative figures obtained from IHC analysis of CAV1, COL4A2, ITGB3, HSPB1, MAP1A and MCAM. The samples labeled with T represent tumor-bearing/tumor-adjacent stroma area from patients' prostate glands; the samples labeled with N represent tumor-adjacent stroma (tumor free) area from the same patients' prostate glands.
Summary statistics based on the t test
| Protein | ||||||
|---|---|---|---|---|---|---|
| CAV1 | COL4A2 | HSPB1 | ITGB3 | MAP1A | MCAM | |
| MExp TS | 195.3 | 188.9 | 177.7 | 190.3 | 188.6 | 194.4 |
| Sd TS | 5.3 | 10.4 | 12.1 | 6.4 | 5.9 | 7.6 |
| MExp NS | 197.4 | 195.7 | 183.4 | 196.0 | 190.0 | 197.2 |
| Sd NS | 6.6 | 4.5 | 8.2 | 3.3 | 5.7 | 5.3 |
| −1.18 | −5.06 | −2.52 | −6.00 | −0.89 | −1.87 | |
| 0.255 | 3.26E-05 | 0.021 | 5.38E-06 | 0.388 | 0.077 | |
MExp: mean expression; Sd: standard deviation
Characteristics of patient cases
| Patent sets | ||
|---|---|---|
| Characteristic | Set A | Set B |
| Number | ||
| Patients | 21 | 78 |
| Normal subjects | 8 | 5 |
| Age for patients only | ||
| Minimum | 55 | 22 |
| Maximum | 87 | 90 |
| Median | 73 | 71 |
| Gleason Score | ||
| 2-6 | 8 (38%) | 24 (31%) |
| 7 (3+4) | 3 (14%) | 19 (24%) |
| 7 (4+3) | 2 (10%) | 17 (22%) |
| 8-10 | 8 (38%) | 17 (22%) |
| Insufficient data | 0 (0%) | 1 (1%) |
| Stage | ||
| T1 | 5 (24%) | |
| T2 | 7 (33%) | 60 (77%) |
| T3 | 9 (43%) | 18 (23%) |
| Lymph Node Status | ||
| N0 | 29 (37%) | |
| N1 | 0 (37%) | |
| Insufficient data | 49 (63%) | |
The percentage in parenthesis represents the percent of patient cases (not including normal subjects) in each category.
Figure 3Schematic of an immunohistochemistry (IHC) stained prostate tissue microarray (TMA) cores showing heterogeneous compartment loci: lumen, epithelial cell, and stroma